SGLT2 Inhibitors in Diabetes & Cardio-Renal Benefits

Understand the role of SGLT2 inhibitors in providing cardio-renal benefits for better health management for the body.

Abstract

In this educational post, I share a clear, first-person journey through modern, evidence-based strategies that leverage SGLT2 inhibitors for cardio-renal protection in patients with diabetes and metabolic syndrome. We will explore the intricate connections between Type 2 Diabetes, Chronic Kidney Disease (CKD), and Cardiovascular Disease, and I will guide you through a detailed case study that showcases a modern, holistic approach to treatment. Drawing from my clinical observations and our multidisciplinary practice in El Paso, Texas, I explain how we integrate chiropractic care, internal medicine oversight, functional medicine, rehabilitation, and personal injury care to optimize outcomes. I also introduce our team structure, in which Dr. Maria Guadalupe Cardenas, MD, Board Certified in Internal Medicine (NPI #1164426749, Texas MD License #J2933), serves as Medical Director and Collaborative Physician at Injury Medical Clinic PA, alongside my role as a Doctor of Chiropractic and an advanced practice registered nurse. This post offers an accessible, step-by-step narrative with clinically relevant physiology, treatment rationales, and actionable protocols to support whole-person cardio-renal health.

My Path Toward Cardio-Renal Integration in Diabetes Care

I am Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. Over the years, my clinical practice has focused on the intersection of metabolic health, musculoskeletal function, and neurophysiology—an integrative space where biochemical and biomechanical pathways meet. Early in my journey, a personal encounter with a loved one’s complications from diabetes impressed upon me how seemingly small choices—nutrition, movement, adherence, and foot care—can transform outcomes. Later, my formal training and work in functional medicine and advanced chiropractic biomechanics refined my approach to combine precise manual therapies, exercise rehabilitation, and medically supervised pharmacologic strategies.

Today, I use modern research on SGLT2 inhibitors to enhance cardio-renal outcomes. At the same time, our clinic’s multidisciplinary model ensures that each intervention is medically appropriate, safely combined, and tailored to the patient’s unique physiology. Our work is about reducing risk, restoring function, and improving quality of life.

Our Integrative Practice Model: A Symphony of Care

At Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas, we have cultivated a unique environment where different disciplines work in concert for the patient’s total well-being. This multidisciplinary setup is typical of progressive integrative and injury-care clinics.

• Medical Management: Our practice is guided by the extensive medical expertise of Dr. Maria Guadalupe Cardenas, MD. Dr. Cardenas is a board-certified internist with an impressive 40-year career. As our Medical Director and Collaborative Physician, she provides essential medical oversight of our patients’ complex conditions, including prescribing and managing medications.
• Chiropractic and Functional Medicine: I, Dr. Alex Jimenez, lead our team with a focus on chiropractic and functional medicine, addressing the body’s structural integrity, biomechanics, and underlying physiological imbalances. This approach is powerful for managing musculoskeletal complications, improving mobility, and reducing pain.
• Comprehensive Services: This collaborative model allows us to offer a full spectrum of services under one roof, including functional medicine, personal injury care, rehabilitation, neuromuscular re-education, and lifestyle medicine.

This synergy ensures that a patient with diabetes receives not only state-of-the-art medical treatment for their blood sugar and organ protection, but also chiropractic adjustments to improve nervous system function, nutritional counseling to overhaul their diet, and physical rehabilitation to help them move again. It’s a 360-degree approach to health that treats the person, not just the disease.

A Patient’s Journey: From Uncontrolled Diabetes to Renewed Health

Let me introduce you to a patient we’ll call R.B., a case that perfectly illustrates the challenges and opportunities in modern diabetes care. When R.B. first came to our clinic, he was a 73-year-old Hispanic male with a 12-year history of type 2 diabetes, hypertension, and hyperlipidemia, and he was struggling despite being on several medications.

Patient Profile & Medications:

• Metformin 1000 mg BID
• Glipizide 10 mg BID with meals
• Linagliptin (Tradjenta) 5 mg daily: A new DPP-4 inhibitor started shortly before his visit.
• Losartan 100 mg daily: For hypertension.
• Hydrochlorothiazide 25 mg daily: A diuretic for blood pressure.
• Simvastatin 40 mg daily: For high cholesterol.
• Glargine (Lantus) Insulin: Recently reduced from 60 units to 42 units.

His lab work painted a concerning picture. His hemoglobin A1C was a staggering 10.2%. His kidney function was declining, with an estimated Glomerular Filtration Rate (eGFR) of 43 and a creatinine level of 1.5. Clinically, he was experiencing dangerously high blood sugars during the day (200-300 mg/dL) yet was waking up with nocturnal hypoglycemia.

This patient was referred to our endocrinology service after a recent hospitalization for hyperglycemia and acute kidney injury. For five years, he had been considered “stable”, but his A1C had never dropped below 8%. This is a critical point: stability at a poor baseline is not true control. He had the trifecta of risk factors that recent clinical trials have focused on:

1. Type 2 Diabetes: With a high A1C of 10.2%.
2. Increased Cardiovascular Risk: Due to co-existing hypertension and hyperlipidemia.
3. Chronic Kidney Disease (CKD): Evidenced by his low eGFR of 43.

Treatment Plan Part 1: Building a Foundation Through Education and Trust

The first step was not to add more medications but to address foundational issues. The patient was glucotoxic—a state where high blood sugar impairs insulin secretion and increases insulin resistance.

Comprehensive Diabetes Self-Management Education (DSME)

We started with intensive education. I discovered R.B. didn’t understand what his medications did. His most significant barrier was a profound fear of low blood sugar. To avoid it, he would preemptively eat carbohydrates throughout the day, driving his blood sugars sky-high. His long-acting insulin would then cause his sugar to plummet at night.

To break this cycle, we made two immediate changes:

• We stopped the glipizide, a sulfonylurea drug notorious for causing hypoglycemia.
• We further decreased his Lantus (glargine) dose to prevent nighttime lows.

Overcoming Barriers to Technology

A major point of resistance was his refusal to use a Continuous Glucose Monitor (CGM). He was terrified of a “big needle” staying under his skin. I showed him a demo CGM device and the tiny, flexible filament—not a needle—that actually sits under the skin. His fear vanished. We applied a sample sensor and ordered his supplies.

Finally, I ordered a C-peptide level. I explained this test to patients using an analogy: “The C-peptide is the candy wrapper, and insulin is the candy. If I see a lot of wrappers in your blood, I know your body is still making its own candy.”

Cardio-Renal Pathophysiology Made Simple

To treat effectively, we must understand the intertwined physiology. I explain these concepts to patients using clear analogies:

• When blood glucose is high, think of syrup or honey. It is sticky and viscous. Your heart has to pump harder to move that thickened fluid, increasing cardiac workload.
• Prolonged exposure to high sugar is inflammatory. If you hold a candy against your cheek for an hour, the tissue feels irritated. Similarly, hyperglycemia stiffens vessel walls and damages the vascular endothelium, including in the kidneys and heart.

The physiology behind these analogies is complex:

• Kidney-glucose dynamics: In hyperglycemia, the kidney’s proximal tubules upregulate SGLT2 transporters, reabsorbing more glucose and sodium. This maladaptive conservation sustains hyperglycemia and reduces sodium delivery to the macula densa, blunting tubuloglomerular feedback and driving glomerular hyperfiltration. Over time, this causes podocyte injury, mesangial expansion, and glomerulosclerosis.
• Heart-kidney axis: Volume overload and neurohormonal activation (RAAS, SNS) perpetuate cardiac remodeling. Increased venous congestion impairs renal perfusion, further activating RAAS—a vicious cycle worsened by insulin resistance and endothelial dysfunction.
• Inflammation and fibrosis: Chronic hyperglycemia and oxidative stress increase TGF-β, NF-κB, and AGE-RAGE signaling, promoting fibrosis in renal and cardiac tissue.
• Autonomic balance: Sympathetic overdrive elevates heart rate and vascular tone, harming diastolic filling and renal microcirculation.

---

Cardiometabolic Risk *Causes & Effects*- Video

---

SGLT2 Inhibitors: How They Work and Why We Use Them

SGLT2 inhibitors (such as empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin) reduce blood glucose by promoting glucose excretion in the urine. Their benefits extend far beyond glucose lowering.

Key mechanisms:

• Renal tubular transport modulation: By blocking sodium-glucose co-transport in the proximal tubule, they increase natriuresis (sodium excretion) and osmotic diuresis (water excretion).
• Restoration of tubuloglomerular feedback: More sodium delivery to the macula densa improves afferent arteriolar tone, reducing intraglomerular pressure and mitigating hyperfiltration.
• Hemodynamic effects: Reduced preload and afterload benefit cardiac function, leading to fewer heart failure events.
• Metabolic shifts: Mild ketogenesis, lower insulin levels, improved insulin sensitivity, and weight reduction collectively support metabolic health.

Why we integrate them:

• Robust evidence demonstrates cardio-renal benefits independent of A1c.
• They complement lifestyle and biomechanical interventions by reducing congestion, improving energy utilization, and lowering systemic inflammation.
• They fit the functional medicine goal of addressing root contributors—hemodynamics, energy metabolism, and renal microvascular stress.

Treatment Plan Part 2: Two Weeks Later – Progress and Precision

Two weeks later, the results were encouraging: blood sugar levels averaged in the 180s, and nocturnal hypoglycemia was gone. The C-peptide test came back within the normal range, confirming his pancreas was still producing insulin.

With his glucotoxicity resolving, it was now safe to introduce a more advanced therapy. Based on his CKD and cardiovascular risk profile, the clear choice was an SGLT2 inhibitor. We started him on Dapagliflozin (Farxiga) 5 mg daily and reduced his glargine dose again.

Clinical Indications and Patient Selection

Our internal medicine oversight by Dr. Cardenas ensures evidence-based selection for SGLT2 inhibitors:

• Type 2 diabetes with high cardiovascular risk or existing heart failure.
• Chronic kidney disease, with or without diabetes, particularly albuminuric CKD.
• Heart failure across ejection fraction phenotypes (HFrEF and HFpEF), per modern trials.

We assess baseline eGFR, albumin-to-creatinine ratio, blood pressure, volume status, and existing medications, such as diuretics and RAAS inhibitors, to anticipate risks.

Safety and Monitoring Protocols

Under Dr.Cardenas’ss medical direction, we implement strict monitoring:

• Renal function: Expect a modest, temporary dip in eGFR initially; monitor for stabilization.
• Volume status: Monitor for dizziness or hypotension; adjust diuretics as needed.
• Genitourinary infections: Counsel on hygiene; monitor for mycotic infections.
• Euglycemic ketoacidosis: Rare; educate on sick-day rules, hydration, and carb intake.
• Foot care: Double down on peripheral vascular assessments and neuropathy screening.

Treatment Plan Part 3: Three Months – Remarkable Improvement

Three months after his initial visit, the transformation was undeniable.

• A1C: Dropped from 10.2% to 8.2%.
• Creatinine: Improved from 1.54 to 1.3.
• eGFR: Increased from 43 to 53.

His kidney function was actively improving! I explained it to him like this: “Remember when I told you high blood sugar makes your blood thick and sticky, like syrup? It forces your kidneys to work overtime. Now that your sugars are better, your blood flows more easily, and your kidneys can filter more efficiently.”

We also switched him from linagliptin to semaglutide (Ozempic) 0.5 mg weekly. Semaglutide is a GLP-1 receptor agonist that not only improves blood sugar control but also promotes weight loss and provides robust cardiovascular protection.

Integrative Chiropractic Care and Rehabilitation

Chiropractic care is not an add-on—it is integral to our approach.

• Autonomic modulation: Dysautonomia in diabetes and heart failure fuels sympathetic dominance. Targeted spinal adjustments and vagal-stimulating breathwork can enhance HRV, reduce resting sympathetic tone, and improve baroreflex sensitivity. This aids renal perfusion and cardiac efficiency.
• Thoracic mobility and respiration: Restricted rib and thoracic spine motion compromises ventilation and venous return. Mobilization improves diaphragmatic excursion, reduces intrathoracic pressures, and supports cardiac filling, synergizing with the preload reduction from SGLT2 inhibitors.
• Gait mechanics and peripheral circulation: Foot and ankle alignment influence plantar pressure and ulcer risk. We correct biomechanical imbalances and prescribe footwear or orthotics.
• Rehabilitation for Capacity Building: Our graded rehabilitation protocols restore functional capacity. Improved skeletal muscle mass enhances glucose uptake (GLUT4-mediated), reduces insulin resistance, and supports cardiac output by improving peripheral oxygen utilization.

From my clinical observations, integrating musculoskeletal optimization with metabolic therapies improves adherence and functional outcomes. Patients who receive targeted manual therapy and movement training are more likely to sustain walking programs, which lower A1C, reduce blood pressure, and enhance heart rate variability.

Treatment Plan Part 4: Seven Months – Approaching Full Remission

Seven months from his first visit, R.B. was a new person.

• Blood Sugar Average: Now 150 mg/dL, with no lows.
• A1C: Further improved to 7.2%, a 3-point drop!
• Creatinine: Now 1.25, within the normal range.
• eGFR: Stabilized at an improved 55.

Most remarkably, he was achieving this without needing mealtime insulin. The combination of Dapagliflozin and Semaglutide was working so effectively that his body’s own insulin, paired with better lifestyle choices, was enough. We officially stopped his prandial lispro.

Why This Matters: From Risk Reduction to Life Quality

This case highlights a new paradigm for diabetes care. We must stop fixating on A1C alone and consider the non-glycemic benefits of medications. By combining SGLT2 inhibitors with integrative chiropractic care, functional medicine, and rehabilitation, we address the mechanisms that drive heart and kidney decline while restoring movement, autonomy, and resilience. The evidence is strong, the physiology compelling, and the patient stories motivating. With cohesive medical oversight from Dr. Maria Guadalupe Cardenas, MD, and a unified clinical team, our approach is safe, rigorous, and deeply human.

Key Takeaways

• SGLT2 inhibitors provide robust cardio-renal benefits through hemodynamic, metabolic, and microvascular mechanisms.
• Integrative chiropractic care enhances autonomic balance, respiration mechanics, and peripheral circulation, synergizing with pharmacotherapy.
• Medical oversight by Dr. Maria Guadalupe Cardenas, MD ensures safety, appropriate selection, and precise monitoring.
• Functional medicine and rehabilitation embed behavior change and strengthen physiology for lasting outcomes.
• Multidisciplinary coordination delivers comprehensive, patient-centered cardio-renal care.

---

References

• American Association of Clinical Endocrinology. (2022). AACE Comprehensive Type 2 Diabetes Management Algorithm.
• American Diabetes Association. (2024). Standards of Medical Care in Diabetes—2024. Diabetes Care.
• Anker, S. D., Butler, J., Filippatos, G., et al. (2021). Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine.
• Cannon, C. P., Pratley, R., Dagogo-Jack, S., et al. (2020). Cardiovascular outcomes with ertugliflozin in type 2 diabetes. New England Journal of Medicine.
• Heerspink, H. J. L., Stefansson, B. V., Correa-Rotter, R., et al. (2020). Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 383(15), 1436–1446.
• Heidenreich, P. A., Bozkurt, B., Aguilar, D., et al. (2022). 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation.
• KDIGO. (2022). KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.
• Marso, S. P., Bain, S. C., Consoli, A., et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 375(19), 1834–1844.
• McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., et al. (2019). Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine.
• Perkovic, V., Jardine, M. J., Neal, B., et al. (2019). Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. New England Journal of Medicine, 380(24), 2295–2306.
• The EMPA-KIDNEY Collaborative Group. (2022). Empagliflozin in patients with chronic kidney disease. New England Journal of Medicine.
• Zelniker, T. A., Wiviott, S. D., Raz, I., et al. (2019). SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet, 393(10166), 31–39.
• Zinman, B., Wanner, C., Lachin, J. M., et al. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine.

Additional Clinical Observations

• Dr. Alex Jimenez on integrative biomechanics and functional outcomes
• Professional profile and clinical insights by Dr. Alex Jimenez

---

SEO tags: SGLT2 inhibitors, cardio-renal benefits, chronic kidney disease, heart failure, type 2 diabetes, integrative chiropractic care, functional medicine, internal medicine oversight, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas, El Paso clinic, diabetes management, rehabilitation, autonomic balance, thoracic mobility, microvascular health, GLP-1 agonists, A1C, eGFR, hypoglycemia, Ozempic, Farxiga, patient education, holistic healthcare, cardio-renal protection, empagliflozin, dapagliflozin, canagliflozin, ertugliflozin, ADA guidelines, AACE guidelines, albuminuria, RAAS system, euglycemic DKA, personal injury care, Mission Plaza Injury Medical Clinic